Gastrointestinal Stromal Tumors Journal | Gastrointestinal Stromal Tumors Articles

EMA Starts New Review of Risks with High-strength Estradiol-containing Creams

FDA Grants Accelerated Approval to Erdafitinib for Metastatic Urothelial Carcinoma

FDA Expands Pembrolizumab Indication for First-line Treatment of NSCLC (TPS ≥1%)

First-line Durvalumab Improves Survival Compared to Chemotherapy in Metastatic NSCLC

Maintenance immunotherapy fails to improve survival in extensive small cell lung cancer [ELCC Press Release]

PROs Were Consistent with the ITT Population Across PD-L1 Subgroups in Patients with Stage III NSCLC Receiving Durvalumab or Placebo

Submitted by Anonymous (not verified) on Wed, 2011-06-01 12:10

Lists:

Editor's choice

...

Latest Articles

Systemic Treatment for Gastrointestinal Stromal Tumor—A State of Art

Xiaolan Feng, Don Morris

Oncology & Hematology Review, 2014;10(2):110–22

Predictive Factors of Efficacy of Sunitinib Therapy in Gastrointestinal Stromal Tumours

Piotr Rutkowski, Monika Jurkowska

European Oncology & Haematology, 2012;8(3):167-172

Modulating the Interaction of Stromal-cell-derived Factor-1/CXCL12 and its Receptor, CXCR4, for Enhanced Mobilisation, Homing and Engraftment of Haematopoietic Stem Cells

Hal E Broxmeyer, Timothy B Campbell

US Hematology, 2007;1(1):43-5

Gastrointestinal Stromal Tumors in the Era of Imatinib—An Overview

Tamara Griffey Barnes

US Oncological Disease, 2007;1(2):85-7

Gastrointestinal Stromal Tumours in the Era of Imatinib – An Overview

Tamara Griffey Barnes

European Oncological Disease, 2007;1(2):60-2

Long-term Disease Control with Imatinib Treatment in Metastatic Gastrointestinal Stromal Tumours

Margaret von Mehren

US Oncological Disease, 2006;1(2):48-50

Early Gastrointestinal Stromal Tumour Resection and Adjuvant Therapy with Imatinib

Peter Hohenberger

US Oncological Disease, 2006;1(2):54-7

Latest Videos

Content Categories:

Gastrointestinal Stromal Tumours

Featured Picture: